In 2026, momentum in China’s small nucleic acid drug sector keeps climbing. As a representative class of nucleic acid therapeutics, small nucleic acid drugs boast enormous development potential. Compared with conventional protein-targeted medicines, they feature high specificity, potent efficacy and durable therapeutic effects.

VCBeat conducted a specialized survey of nearly 100 domestic relevant enterprises. It screened companies based on multiple dimensions including financing strength, product pipelines under development, cross-border partnerships and core teams. Furthermore, it categorized five segmented tracks by drug mechanisms of action and compiled a comprehensive industrial map for small nucleic acid drugs.

This map clearly presents the number of enterprises and core technological focuses across the five key segmented tracks. It also compiles basic profiles of nearly 100 companies, covering founding date, business location, staff size, contact information, official websites, financing history and corporate updates.

VCBeat has built in-depth connections with all enterprises on the map, offering exclusive cooperation channels and providing full-spectrum, authoritative data to support industrial planning, trend analysis, business collaboration and investment decision-making.